Occurrence of circulating 7-deoxyaglycone metabolites of 4'-deoxydoxorubicin in man.

Abstract:

:In five cancer patients we have determined the pharmacokinetics of 4'-deoxydoxorubicin (4'-DOX), its alcoholic metabolite 4'-deoxydoxorubicinol and the occurrence of circulating 7-deoxyaglycone metabolites. The 7-deoxyaglycone of the alcohol metabolite, the major aglycone of Adriamycin (ADR) present in man, was not detected in any serum sample. The 7-deoxyaglycone of the parent drug, which appears in concentrations in excess of 30 ng/ml after ADR administration, was detected in only 2/5 patients in trace amounts. These preliminary data indicate a difference in biotransformation between ADR and 4'-DOX despite their close structural similarities.

authors

Cummings J,Kerr DJ,Kaye SB

doi

10.1007/BF00570499

subject

Has Abstract

pub_date

1987-01-01 00:00:00

pages

263-4

issue

3

eissn

0344-5704

issn

1432-0843

journal_volume

20

pub_type

杂志文章
  • Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models.

    abstract::UCN-01 (7-hydroxystaurosporine; NSC 638850) is a protein kinase antagonist selected for clinical trial based in part on evidence of efficacy in a preclinical renal carcinoma xenograft model. Schedule studies and in vitro studies suggested that a 72-h continuous infusion would be appropriate. In rats and dogs, maximum ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s002800051080

    authors: Sausville EA,Lush RD,Headlee D,Smith AC,Figg WD,Arbuck SG,Senderowicz AM,Fuse E,Tanii H,Kuwabara T,Kobayashi S

    更新日期:1998-01-01 00:00:00

  • Interleukin-1 receptor antagonist attenuates cyclophosphamide-induced mucositis in a murine model.

    abstract:PURPOSE:Cyclophosphamide is a cytotoxic chemotherapy drug that causes severe damages to hematopoietic and gastrointestinal systems. The aim of this study is to evaluate the protective effects of recombinant human interleukin-1 receptor antagonist (rhIL-1Ra) on chemotherapy-induced mucositis (CIM) in a murine model of c...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-010-1439-1

    authors: Xiang D,Guo Y,Zhang J,Gao J,Lu H,Zhu S,Wu M,Yu Y,Han W

    更新日期:2011-06-01 00:00:00

  • Toxicity and metabolism of 3'-deoxyadenosine N1-oxide in mice and Ehrlich ascites tumor cells.

    abstract::The toxic effect of 3'-deoxyadenosine N1-oxide (3'-dANO) on mice, on their different organs, and on Ehrlich ascites tumor cells was studied. In both healthy and tumour-bearing animals, the lethal dose for 10% of the mice receiving i.p. injections (LD10) of 3'-dANO was estimated to be about 300 mg/kg x 4 days in one mo...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00686398

    authors: Svendsen KR,Overgaard-Hansen K,Frederiksen S,Engelholm SA,Pedersen NT,Vindeløv LL

    更新日期:1992-01-01 00:00:00

  • Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates.

    abstract:PURPOSE:Thalidomide, originally developed as a sedative, was subsequently identified to have antiangiogenic properties. Lenalidomide is an antiangiogenic and immunomodulatory agent that has been utilized in the treatment of patients with brain tumors. We studied the pharmacokinetics and cerebrospinal fluid (CSF) penetr...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-011-1781-y

    authors: Muscal JA,Sun Y,Nuchtern JG,Dauser RC,McGuffey LH,Gibson BW,Berg SL

    更新日期:2012-04-01 00:00:00

  • Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report.

    abstract:PURPOSE:Irinotecan-induced gut toxicity is mediated in part by Toll-Like receptor 4 (TLR4) signalling. The primary purpose of this preclinical study was to determine whether blocking TLR4 signalling by administering (-)-naloxone, a TLR4 antagonist, would improve irinotecan-induced gut toxicity. Our secondary aim was to...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-016-3223-3

    authors: Coller JK,Bowen JM,Ball IA,Wardill HR,van Sebille YZ,Stansborough RL,Lightwala Z,Wignall A,Shirren J,Secombe K,Gibson RJ

    更新日期:2017-02-01 00:00:00

  • 2-Methoxyestradiol inhibits hepatocellular carcinoma cell growth by inhibiting Cdc25 and inducing cell cycle arrest and apoptosis.

    abstract:PURPOSE:2-Methoxyestradiol (2-ME) is a physiological metabolite of estrogen, which can inhibit growth of many types of tumor cells, including hepatocellular carcinoma, both in vitro and in vivo. The exact mechanisms of its action are still unclear. We have studied the mechanisms of growth inhibition of several of human...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-007-0670-x

    authors: Kar S,Wang M,Carr BI

    更新日期:2008-10-01 00:00:00

  • Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas.

    abstract:OBJECTIVES:The aim of this phase II study was to evaluate the response rate to gemcitabine combined with cisplatin in patients with locally advanced, metastatic or recurrent biliary tract cancer who had received no prior chemotherapy. METHODS:The treatment consisted of cisplatin 70 mg/m(2) in intravenous infusion foll...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s00280-007-0444-5

    authors: Lee J,Kim TY,Lee MA,Ahn MJ,Kim HK,Lim HY,Lee NS,Park BJ,Kim JS,Korean Cancer Study Group.

    更新日期:2008-01-01 00:00:00

  • Relationship between tumor cell density and drug concentration and the cytotoxic effects of doxorubicin or vincristine: mechanism of inoculum effects.

    abstract::When tumor cell density increases, the cytotoxic activity of certain anticancer agents, such as vincristine (VCR) and doxorubicin (DXR), progressively decreases. This phenomenon is termed the inoculum effect. Since VCR and DXR are less active in an acidic environment, we questioned whether the inoculum effects could h...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00695987

    authors: Kobayashi H,Takemura Y,Ohnuma T

    更新日期:1992-01-01 00:00:00

  • Hyperacetylation enhances the growth-inhibitory effect of all-trans retinoic acid by the restoration of retinoic acid receptor beta expression in head and neck squamous carcinoma (HNSCC) cells.

    abstract::The chemotherapeutic effects of all-trans-retinoic acid (atRA) are mediated by the retinoic acid receptor beta (RARbeta), but RARbeta expression is reduced in a number of head and neck carcinoma (HNSCC) cells which causes resistance to RA treatment in half the patients with HNSCC. The possible mechanism for the reduce...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-004-0970-3

    authors: Whang YM,Choi EJ,Seo JH,Kim JS,Yoo YD,Kim YH

    更新日期:2005-11-01 00:00:00

  • Activity of continuous-infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil.

    abstract::We have recently demonstrated that continuous-infusion (CI) 5-fluorouracil (FU) eradicates human colon carcinoma cells made resistant to bolus FU in vitro. In addition, in the same experimental system, the mechanisms of resistance to pulse and CI FU were found to be different. These observations led us to test the cli...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00685339

    authors: Mori A,Bertoglio S,Guglielmi A,Aschele C,Bolli E,Tixi L,Rosso R,Sobrero A

    更新日期:1993-01-01 00:00:00

  • A highly sensitive enzyme-linked immunosorbent assay for etoposide using beta-D-galactosidase as a label.

    abstract::A highly sensitive enzyme-linked immunosorbent assay (ELISA) for etoposide (EP) was developed, which is capable of accurately measuring as little as 40 pg EP/ml. Anti-EP sera were obtained by immunizing rabbits with EP conjugated with mercaptosuccinyl bovine serum albumin (MS.BSA) using N-[beta-(4-diazophenyl)ethyl]ma...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00689094

    authors: Saita T,Fujiwara K,Kitagawa T,Mori M,Takata K

    更新日期:1990-01-01 00:00:00

  • Utilization of the HTSCA and CFU-C assay to identify two new 2-chloroethylnitrosourea congeners of amino acid amides with increased in vitro activity against human glioma compared with BCNU.

    abstract::AspCNU and SarCNU are two amino acid amide congeners (L-asparaginamide and sarcosinamide congeners) of chloroethylnitrosoureas. The in vitro myelotoxicity of these agents compared with BCNU at 1-8 micrograms/ml was determined in bone marrow cells from normal volunteers in the CFU-C assay. AspCNU and SarCNU were signif...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00434356

    authors: Panasci LC,Dufour M,Chevalier L,Isabel G,Lazarus P,McQuillan A,Arbit E,Brem S,Feindel W

    更新日期:1985-01-01 00:00:00

  • IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells.

    abstract:BACKGROUND:Inhibitors of heat shock protein (Hsp) 90 induce apoptosis in multiple myeloma (MM) cells, but the molecular mechanisms underlying this cytotoxic outcome are not clear. Here, we investigate the effect of IPI-504, a novel and highly soluble inhibitor of the Hsp90 ATPase activity, on the unfolded protein respo...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-007-0546-0

    authors: Patterson J,Palombella VJ,Fritz C,Normant E

    更新日期:2008-05-01 00:00:00

  • Comparison of the potency of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factors in neutropenic and nonneutropenic CD rats.

    abstract::Recent studies in human bone-marrow culture and healthy human volunteers suggest that lenograstim [glycosylated, recombinant human granulocyte colony-stimulating factor (rHuG-CSF) produced in Chinese hamster ovary (CHO) cells] has greater in vivo potency than filgrastim [nonglycosylated, methionine-extended recombinan...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002800050570

    authors: Nohynek GJ,Plard JP,Wells MY,Zerial A,Roquet F

    更新日期:1997-01-01 00:00:00

  • Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations.

    abstract:PURPOSE:Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are key drugs in the treatment of non-small cell lung cancer (NSCLC) harboring EGFR activating mutations. We assessed the efficacy and safety of one EGFR tyrosine kinase inhibitor, erlotinib, in elderly Japanese patients with EGFR-mutated NSCLC....

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s00280-015-2784-x

    authors: Inoue Y,Inui N,Asada K,Karayama M,Matsuda H,Yokomura K,Koshimizu N,Imokawa S,Yamada T,Shirai T,Kasamatsu N,Suda T

    更新日期:2015-07-01 00:00:00

  • Development of anti-angiogenic tyrosine kinases inhibitors: molecular structures and binding modes.

    abstract:PURPOSE:Since the hypothesis that solid tumors cause angiogenesis by secreting pro-angiogenic factors was introduced, research on angiogenesis has proceeded continuously. Development of inhibitors targeting the angiogenic tyrosine kinases, to block downstream signal transduction pathways, has become an important approa...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,评审

    doi:10.1007/s00280-016-2961-6

    authors: Zhang J,Zhang L,Wang Y,Zhao G

    更新日期:2016-05-01 00:00:00

  • Lack of effect of cisplatin on i.v. L-PAM plasma pharmacokinetics in ovarian cancer patients.

    abstract::Melphalan (L-PAM) pharmacokinetics were investigated in nine ovarian cancer patients before and after cisplatin (DDP) treatment. When L-PAM was given 24 h before DDP, the elimination half-life (t 1/2 beta), plasma clearance (Clp), and volume of distribution (Vd beta) of L-PAM were, respectively: 46.4 +/- 6.7 min, 20.5...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00254189

    authors: Zucchetti M,D'Incalci M,Willems Y,Cavalli F,Sessa C

    更新日期:1988-01-01 00:00:00

  • Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group study.

    abstract:PURPOSE:This prospective multicenter phase II study was carried out to investigate the efficacy, safety and pharmacokinetics of S-1 monotherapy in elderly patients over 75 years of age, with unresectable advanced or recurrent gastric cancer. METHODS:Patients had measurable or evaluable lesions according to the Japanes...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s00280-009-1114-6

    authors: Koizumi W,Akiya T,Sato A,Sakuyama T,Sasaki E,Tomidokoro T,Hamada T,Fujimori M,Kikuchi Y,Shimada K,Mine T,Yamaguchi K,Sasaki T,Kurihara M

    更新日期:2010-05-01 00:00:00

  • MITF suppression by CH5552074 inhibits cell growth in melanoma cells.

    abstract:PURPOSE:Although treatment of melanoma with BRAF inhibitors and immune checkpoint inhibitors achieves a high response rate, a subset of melanoma patients with intrinsic and acquired resistance are insensitive to these therapeutics, so to improve melanoma therapy other target molecules need to be found. Here, we screene...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-017-3317-6

    authors: Aida S,Sonobe Y,Yuhki M,Sakata K,Fujii T,Sakamoto H,Mizuno T

    更新日期:2017-06-01 00:00:00

  • Growth-inhibitory effects of the synthetic retinoid CD437 against ovarian carcinoma models in vitro and in vivo.

    abstract::The activity of CD437¿6-[3-(1-adamantyl)-4 hydroxyphenyl]-2-naphthalene carboxylic acid¿, a relatively selective activator of RAR-gamma, was evaluated against four human ovarian-carcinoma cell lines : PE01, PE04 (a Pt-resistant in vivo-derived counterpart of PE01), PE01CDDP (a Pt-resistant in vitro-derived model of PE...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002800050841

    authors: Langdon SP,Rabiasz GJ,Ritchie AA,Reichert U,Buchan P,Miller WR,Smyth JF

    更新日期:1998-01-01 00:00:00

  • Evaluation of cardiac activity and pharmacokinetic analysis of 3H-adriamycin in patients pretreated with beta-methyldigoxin.

    abstract::The consequences at the cardiac level of adriamycin treatment alone or in association with the cardiac glycoside beta-methyldigoxin, were evaluated with reference to the PEP/LVET ratio, heart rate, and minimum blood pressure. The variation usually seen in the PEP/LVET ratio when adriamycin is administered alone was no...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00258290

    authors: Di Fronzo G,Bertuzzi A,Ronchi E,Villani FP,Ronchetti L

    更新日期:1979-01-01 00:00:00

  • Administration of oxaliplatin to a pregnant woman with rectal cancer.

    abstract:PURPOSE:The platinum agent oxaliplatin could be useful in treatment of cancer in pregnant women, but it is fetotoxic in rats and its effect on the human fetus is unknown. METHODS:Oxaliplatin was administered to a 25-year-old pregnant woman with metastatic rectal cancer from 20 to 30 weeks gestational age as part of th...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-008-0731-9

    authors: Gensheimer M,Jones CA,Graves CR,Merchant NB,Lockhart AC

    更新日期:2009-01-01 00:00:00

  • Safety of topotecan monotherapy for relapsed small cell lung cancer patients with pre-existing interstitial lung disease.

    abstract:PURPOSE:To investigate the safety of intravenous topotecan monotherapy for relapsed small cell lung cancer (SCLC) patients with pre-existing interstitial lung disease (ILD). METHODS:A total of 77 patients who received topotecan for the treatment of relapsed SCLC between April 2007 and April 2014 were reviewed. Patient...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-015-2816-6

    authors: Enomoto Y,Inui N,Imokawa S,Karayama M,Hasegawa H,Ozawa Y,Matsui T,Yokomura K,Suda T

    更新日期:2015-09-01 00:00:00

  • Preoperative radiotherapy with capecitabine and mitomycin C in locally advanced rectal carcinoma.

    abstract:PURPOSE:To evaluate the efficacy and safety of preoperative radiotherapy with capecitabine and mitomycin C in patients with locally advanced rectal cancer. METHODS:A prospective, open-label, non-randomized, phase II study was performed on 49 patients with locally advanced rectal cancer. Preoperative radiotherapy was c...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s00280-010-1469-8

    authors: Stojanovic S,Popov I,Radosevic-Jelic L,Micev M,Borojevic N,Nikolic V,Krivokapic Z,Kecmanovic D,Gavrilovic D,Kezic I

    更新日期:2011-09-01 00:00:00

  • Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor.

    abstract:PURPOSE:There is considerable current interest in the use of thalidomide as a single agent or in combination with drugs such as cyclophosphamide in the treatment of multiple myeloma and other cancers. Our previous work has shown that thalidomide potentiates the antitumour activity of both cyclophosphamide and 5,6-dimet...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-003-0753-2

    authors: Chung F,Wang LC,Kestell P,Baguley BC,Ching LM

    更新日期:2004-05-01 00:00:00

  • Effects of cyclosporine A on the hepatobiliary disposition and hepatic uptake of etoposide in an isolated perfused rat liver model.

    abstract:PURPOSE:A recirculating isolated perfused rat liver model was used to investigate the hepatobiliary disposition of etoposide and the effects of cyclosporine A (CyA) on the pattern of drug disposition in the bile and uptake in the liver. METHODS:The portal vein, bile duct, and superior vena cava were cannulated in four...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-015-2719-6

    authors: Khezrian M,Sheikholeslami B,Dadashzadeh S,Lavasani H,Rouini M

    更新日期:2015-05-01 00:00:00

  • High dose melphalan in children with advanced malignant disease. A pharmacokinetic study.

    abstract::Nine children with poor-prognosis malignancies--seven with advanced neuroblastoma and two with metastatic Ewing's sarcoma--were given high doses of melphalan (HDM), 150 mg/m2 (3 patients) and 180 mg/m2 (6 patients), as a 'late intensification' agent combined with noncryopreserved autologous bone marrow transplants. Me...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00263898

    authors: Ninane J,Baurain R,de Selys A,Trouet A,Cornu G

    更新日期:1985-01-01 00:00:00

  • Dosing algorithm revisit for busulfan following IV infusion.

    abstract:PURPOSE:Busulfan (Bu) exposure is critical for efficacy and safety. Body weight (BW), or adjusted ideal body weight (AIBW)-based dosing (WBD) algorithm, has been used in hematopoietic stem cell transplantation (HSCT). A recently completed phase 2 study revealed that 33.6 % of the subjects were under-, or over-exposed, ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-014-2660-0

    authors: Wang Y,Kato K,Le Gallo C,Armstrong E,Rock E,Wang X

    更新日期:2015-03-01 00:00:00

  • Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC).

    abstract:PURPOSE:The sequence bendamustine (B) + Irinotecan (I) followed by etoposide (E) + carboplatin (C) was hypothesized to increase progression-free survival (PFS) and overall survival (OS) in untreated extensive-disease small cell lung cancer (EDSCLC) patients compared to historical controls by exploiting mitotic catastro...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-015-2869-6

    authors: Allendorf DJ,Bordoni RE,Grant SC,Saleh MN,Reddy VB,Jerome ML,Dixon PM,Miley DK,Singh KP,Robert F

    更新日期:2015-11-01 00:00:00

  • Pharmacokinetics and tissue distribution of idarubicin and its active metabolite idarubicinol in the rabbit.

    abstract::A three-compartment model was fitted to idarubicin data in a NONMEM pooled-data approach. Clearance (CL) of 221.7 ml/min was relatively high, and drug distribution was rapid (CLD = 248.3 ml/min) and extensive [steady-state volume of distribution (Vss) 24 1]. The area under the concentration-time curve (AUC) of idarbic...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002800050614

    authors: Looby M,Linke R,Weiss M

    更新日期:1997-01-01 00:00:00